Sukumar, Smrithi
Orkaby, Ariela R.
Schwartz, Janice B.
Marcum, Zachary
Januzzi, James L.
Vaduganathan, Muthiah
Warraich, Haider J. http://orcid.org/0000-0001-9493-1372
Article History
Accepted: 2 June 2022
First Online: 20 June 2022
Declarations
:
: AO is supported by VA CSR&D CDA-2 award IK2-CX001800 and NIA GEMSSTAR award R03-AG060169. HW is an advisor for Embrace Prevention Care. MV is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (National Institutes of Health [NIH] National Center for Advancing Translational Sciences Award UL 1TR002541); serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa; and has participated on clinical end point committees for studies sponsored by Novartis (including the PARAGON-HF trial) and the NIH. JJ is supported by the Hutter Family Professorship; is a trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received grant support from Abbott Diagnostics, Applied Therapeutics, Innolife, and Novartis; has received consulting income from Abbott Diagnostics, Boehringer Ingelheim, Janssen, Novartis, and Roche Diagnostics; and participates in clinical end point committees/data safety monitoring boards for AbbVie, Siemens, Takeda, and Vifor.
: This article does not contain any studies with human or animal subjects performed by any of the authors.